While the number of patients in this subgroup analysis are relatively small, the findings are suggestive of a benefit to the addition of a FLT3 inhibitor to a lower-intensity backbone in older adults with newly diagnosed FLT3-mutated AML who are unfit for intensive chemotherapy. Here, FLT3 is linked to acute myeloid leukemia.